We hypothesize that the addition of cetuximab to twice weekly paclitaxel/cisplatin
concurrent chemoradiotherapy as the adjunctive therapy before esophagectomy or as a
definitive CRT would improve the therapeutic efficacy of TP-CCRT in patients with
loco-regional esophageal squamous cell carcinoma.

Inclusion Criteria:

1. Pathologically proven squamous cell carcinoma of esophagus.

2. Loco-regional diseases, which are defined by TNM system of American Joint Committee
on Cancer (AJCC) Cancer Staging System (6th edition) in 2002, fulfilling one of the
following criteria:

Completion Date:

Related Keywords:

Name

Location

We are a Cancer Social Network, Resource Directory & Education Hub supporting all those affected by cancer. knowcancer.com is intended to be solely for informational purposes and should not be a substitute for professional medical advice, diagnosis or treatment.